N@N

Edward Tenthoff Maintained (ARWR) at Buy with Increased Target to $59 on, Jun 2nd, 2023

Edward Tenthoff of Piper Sandler, Maintained "Arrowhead Pharmaceuticals, Inc." (ARWR) at Buy with Increased Target from $52 to $59 on, Jun 2nd, 2023.

Edward has made no other calls on ARWR in the last 4 months.

There are 9 other peers that have a rating on ARWR. Out of the 9 peers that are also analyzing ARWR, 3 agree with Edward's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Mani Foroohar of "SVB Leerink" Downgraded from Buy to Hold and Held Target at $40 on, Friday, May 12th, 2023
• Michael Ulz of "Morgan Stanley" Maintained at Hold with Increased Target to $40 on, Wednesday, May 3rd, 2023
• William Pickering of "Bernstein" Initiated at Hold and Held Target at $27 on, Tuesday, March 21st, 2023

These are the ratings of the 6 analyists that currently disagree with Edward

---

• Luca Issi of "RBC Capital" Reiterated at Buy and Held Target at $60 on, Wednesday, May 3rd, 2023
• Madhu Kumar of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $73 on, Wednesday, May 3rd, 2023
• David Hoang of "SMBC Nikko" Initiated at Buy and Held Target at $80 on, Wednesday, April 26th, 2023
• Patrick Trucchio of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $90 on, Friday, February 10th, 2023
• Mayank Mamtani of "B. Riley Securities" Maintained at Strong Buy with Decreased Target to $55 on, Wednesday, February 8th, 2023
• Joel Beatty of "Baird" Maintained at Buy with Decreased Target to $58 on, Tuesday, February 7th, 2023

Contributing Sources

---